Brief: Exelixis And Merck Sign Clinical Development Collaboration

Exelixis

14/10/2024 13:08

Oct 14 (Reuters) - Exelixis Inc  EXEL.O :
    * EXELIXIS AND MERCK SIGN CLINICAL DEVELOPMENT COLLABORATION
TO
EVALUATE INVESTIGATIONAL ZANZALINTINIB IN COMBINATION WITH
KEYTRUDA® (PEMBROLIZUMAB) IN HEAD AND NECK CANCER AND IN
COMBINATION WITH WELIREG® (BELZUTIFAN) IN RENAL CELL CARCINOMA

Source text for Eikon:  ID:nBw1mP24Fa 
Further company coverage:  EXEL.O 

 ((Reuters.Briefs@thomsonreuters.com;))